The global Biologicals Market size was USD 657.51 billion in 2025, projected to reach USD 1,659.47 billion by 2035, growing at a CAGR of 9.7% from 2026 to 2035. Key growth drivers include sustained GLP-1 receptor agonist demand, accelerating biosimilar approvals, expanding oncology biologics pipelines, and scaling cell and gene therapy manufacturing, with North America leading the market with approximately 44% share.
At Next Move Strategy Consulting, we understand that insightful market research is the cornerstone of successful business decisions. That's why we employ a robust and multifaceted approach, combining various methodologies to deliver the most accurate and actionable data for our clients.
Research Landscape
We navigate the world of research with two primary approaches:
Our qualitative research methodologies involve immersive techniques such as in-depth interviews, focus groups, and observational studies. By engaging directly with individuals and stakeholders, we uncover valuable insights that quantitative data alone may overlook.
Quantitative Research
In tandem with qualitative methodologies, NMSC leverages the power of Quantitative Research to provide a robust foundation of numerical insights. Through systematic data collection and analysis, we quantify patterns, preferences, and market trends, offering a comprehensive view of the business landscape.
Our quantitative research approach employs diverse tools, including surveys, experiments, and statistical modelling. These methodologies enable us to gather data from a large and representative sample, ensuring the statistical significance of our findings. By employing structured questionnaires and standardized data collection methods, we guarantee the reliability and validity of the information we present to our clients.
Quantitative research is particularly effective in measuring the prevalence of trends, assessing market size, and gauging the impact of various factors on consumer behavior. The numerical precision attained through this approach equips our clients with actionable insights, facilitating data-driven decision-making and strategy formulation.
We deploy a specialized arsenal of techniques tailored to meet your unique requirements. Here's a glimpse into our comprehensive toolbox:
The stage entails acquiring market data or relevant information through various sources and methodologies.
We utilize both top-down and bottom-up approaches in market research analysis to achieve a comprehensive understanding of the market dynamics, leveraging the broad perspective of industry trends and macroeconomic factors alongside detailed insights from specific segments and individual companies.
We conduct Porter's Five Forces analysis to evaluate the competitive landscape of an industry, providing us with insights into factors that affect profitability and strategic positioning.
We utilize a forecasting model to predict future consumption by considering parameters like population, economics, regulations, market competition, drivers, constraints, technology, and pricing. We also employ statistical techniques such as multilinear regression, exponential smoothing, moving average, ARIMA, and Monte Carlo simulations for accurate predictions. In econometric forecasting, we analyzed short-term and long-term event impacts, attributing values based on regulatory frameworks, economic factors, and market events.
The global Biologicals Market size was valued at USD 657.51 Billion in 2025 and is estimated at USD 721.29 Billion in 2026, forecast to reach USD 1,659.47 Billion by 2035, expanding at a 9.7% CAGR between 2026 and 2035. North America leads with approximately 44% share, while under product modality, Monoclonal Antibodies dominates with approximately 39% share.
GLP-1 receptor agonist demand, expanding biosimilar approval activity, and scaling cell and gene therapy pipelines are reshaping revenue distribution across every segmentation axis through 2035.
Values in USD Billion
By Product Modality: Monoclonal Antibodies held the largest share of approximately 39% (USD 258.00 Billion) in 2025; Nucleic Acid Therapeutics is the fastest-growing sub-segment at 19.5% CAGR from 2026–2035.
By Product Status: Reference Biologics held the largest share of approximately 79% (USD 520.00 Billion) in 2025; Biosimilars is the fastest-growing sub-segment at 16.2% CAGR from 2026–2035.
By Therapeutic Area: Oncology held the largest share of approximately 27% (USD 180.00 Billion) in 2025; Endocrine and Metabolic Disease is the fastest-growing sub-segment at 14.6% CAGR from 2026–2035.
By Distribution Channel: Direct Institutional Sales held the largest share of approximately 39% (USD 258.00 Billion) in 2025; Specialty Pharmacy Networks is the fastest-growing sub-segment at 14.6% CAGR from 2026–2035.
Dominant Region: North America dominated with approximately 44% revenue share (USD 290.00 Billion) in 2025.
Fastest-Growing Region: Asia-Pacific is expected to register the highest CAGR of 12.5% during 2026–2035.
Dominant Country: U.S. led with approximately USD 246.00 Billion in 2025.
Fastest-Growing Country: India is the fastest-growing country at approximately 15.6% CAGR from 2026–2035.
Between 2026 and 2035, the Biologicals Market is set to generate an absolute dollar opportunity of USD 938.18 Billion, positioning GLP-1 franchises and biosimilar-eligible reference products as compelling areas for capital allocation.
According to NMSC analysis, expanding FDA and EMA biosimilar authorization capacity is compressing the historical multi-year gap between patent expiry and competitive entry, a shift that increasingly determines how originator companies structure lifecycle management for their largest biologic franchises.
This report covers human therapeutic and preventive biological medicines, including monoclonal antibodies, recombinant proteins and peptides, vaccines, plasma derived therapies, cell and gene therapies, nucleic acid therapeutics, and live biotherapeutics. It excludes agricultural biological products such as biopesticides, biofertilizers, and biostimulants , which serve agricultural rather than human medicinal applications. In this report, the terms biologicals and biologics refer interchangeably to human medicinal products manufactured from or derived using living cells and organisms, spanning reference products, biosimilars, and other follow-on biologics across every major therapeutic area.
The market has evolved from a narrow set of recombinant insulin and interferon products in the 1980s into a broad category spanning oncology antibodies, GLP-1 metabolic peptides, and mRNA and cell-based platforms. The FDA regulates biologics under the Public Health Service Act, with biosimilars approved through the abbreviated 351(k) pathway established by the 2009 Biologics Price Competition and Innovation Act. In March 2026, the FDA issued updated draft guidance recommending a more streamlined approach to clinical pharmacokinetic testing for biosimilars when scientifically justified , a change expected to shorten development timelines industry-wide.
Four structural trends are reshaping product development, regulatory strategy, and commercial positioning across the Biologicals Market.
GLP-1 receptor agonist therapies have become the largest single growth engine within recombinant proteins and peptides. Eli Lilly and Company reported 2025 revenue of $65.2 billion, up 45% year over year, with Mounjaro and Zepbound together generating $36.5 billion, or roughly 56% of total sales. The FDA approved Lilly's oral GLP-1 therapy Foundayo in the second quarter of 2026 , while Novo Nordisk A/S launched an oral version of Wegovy in January 2026, extending metabolic disease treatment beyond injectable formats.
Regulatory streamlining is compressing the timeline for biosimilars to reach patients following originator patent expiry. By the end of 2025, FDA had approved 81 biosimilars through CDER for 20 reference products, including eight denosumab biosimilars approved during 2025 referencing Prolia and Xgeva , while the European Medicines Agency authorized a record 44 biosimilars in 2025. The FDA's March 2026 draft guidance recommends streamlining unnecessary clinical pharmacokinetic testing for biosimilars when scientifically justified.
Autologous and allogeneic cell therapy manufacturers are investing in automated, closed-system production to reduce per-patient manufacturing cost and turnaround time. Commercial CAR T-cell therapies approved for hematologic malignancies are expanding into earlier treatment lines, widening the eligible patient population beyond initial relapsed and refractory indications. Manufacturers with validated, scaled production capacity increasingly differentiate on vein-to-vein turnaround time as a direct driver of patient access.
Small interfering RNA and antisense oligonucleotide platforms are expanding biologic treatment options for chronic conditions previously addressed only by small-molecule or antibody therapies. Approved siRNA therapeutics targeting cardiovascular and metabolic liver conditions have demonstrated durable dosing intervals of several months per injection, a profile that supports strong patient adherence relative to daily or weekly alternatives. Pharmaceutical companies are increasingly licensing nucleic acid delivery platforms from specialized developers rather than building in-house capability from the ground up.
| Sustained GLP-1 receptor agonist demand for metabolic and obesity indications | driver | +2.8% | North America, Europe | 2026–2032 |
| Accelerating biosimilar approval activity following patent expiry of major franchises | driver | +2.1% | North America, Europe | 2026–2035 |
| Expanding oncology biologics pipeline including antibody-drug conjugates | driver | +1.6% | Global | 2026–2035 |
| Scaling cell and gene therapy manufacturing capacity and reimbursement pathways | driver | +1.2% | North America, Europe, Asia-Pacific | 2026–2033 |
| Growing biosimilar manufacturing investment across Asia-Pacific markets | driver | +0.9% | Asia-Pacific | 2026–2035 |
| Rising nucleic acid therapeutic approvals across chronic disease indications | driver | +0.6% | North America, Europe | 2026–2032 |
| High per-patient cost of cell and gene therapies limiting broad reimbursement | restraint | −1.3% | Middle East & Africa, Latin America | 2026–2032 |
| Cold-chain and biologic manufacturing infrastructure gaps in emerging markets | restraint | −0.8% | Middle East & Africa, Latin America | 2026–2030 |
| Patent litigation and interchangeability requirements delaying biosimilar market entry | restraint | −0.5% | North America | 2026–2030 |
Sustained GLP-1 receptor agonist demand for metabolic and obesity indications is the primary driver of the Biologicals Market. Eli Lilly and Company raised its 2026 full-year revenue guidance to between $82.0 billion and $85.0 billion following first-quarter growth of 56%, driven substantially by Mounjaro and Zepbound volume gains. This single therapeutic franchise illustrates how metabolic disease biologics have shifted from a specialty category into one of the largest revenue pools within the broader biologics market.
Accelerating biosimilar approval activity is expanding patient access while redistributing revenue away from aging reference product franchises. The FDA's March 2026 guidance reducing clinical pharmacokinetic testing requirements for qualifying monoclonal antibody biosimilars is expected to shorten average development timelines for future submissions. This regulatory shift, combined with the European Medicines Agency's record 44 biosimilar authorizations in 2025, is compressing the commercial window in which originator biologics retain exclusive market access.
High per-patient cost of cell and gene therapies restrains broad reimbursement and adoption outside high-income healthcare systems. Single-administration cell and gene therapies commonly carry list prices exceeding several hundred thousand dollars per patient, a cost structure that few national health systems outside North America and Western Europe can reimburse at scale. Manufacturers face particular exposure in Middle Eastern, African, and Latin American markets, where cold-chain and specialized administration infrastructure remains limited outside major urban medical centers .
Oral GLP-1 formulations present a whitespace opportunity for manufacturers seeking to expand beyond injectable-only treatment paradigms. Companies that commercialize durable oral peptide delivery technology stand to capture patients who decline injectable therapy, expanding the addressable population within the Recombinant Proteins and Peptides segment.
Asia-Pacific manufacturing capacity presents an underpenetrated opportunity for biosimilar producers seeking to serve both domestic and export markets. Manufacturers that achieve FDA and EMA facility qualification can secure durable, multi-year supply contracts as reference biologics lose exclusivity across major markets simultaneously.
Automated, closed-system manufacturing creates an opportunity for cell therapy developers seeking to reduce per-patient production cost and turnaround time. Early movers that scale decentralized or point-of-care manufacturing can differentiate with treatment centers pursuing broader patient access beyond specialized academic medical centers .
The regulatory framework for biologicals plays a critical role in determining product development timelines, manufacturing requirements, clinical validation, and market access. Regulatory pathways, cGMP standards, clinical trial requirements, reimbursement policies, and international trade controls collectively influence commercialization. While stringent oversight strengthens product safety and quality, evolving regulations can increase compliance costs and create market-entry challenges for manufacturers.
| Region | 2025 (USD Billion) | 2035 (USD Billion) | CAGR (%) |
|---|---|---|---|
| North America | $10.0 USD Billion | $40.0 USD Billion | 9.0% |
| Europe | $17.1 USD Billion | $51.1 USD Billion | 27.0% |
| Asia-Pacific | $24.2 USD Billion | $62.2 USD Billion | 25.0% |
| Middle East & Africa | $31.3 USD Billion | $73.3 USD Billion | 23.0% |
| Latin America | $38.4 USD Billion | $84.4 USD Billion | 12.0% |
The Biologicals Market features a moderately consolidated competitive landscape, with diversified large-molecule originators competing alongside specialized biosimilar and cell therapy developers.
| Dimension | Description |
|---|---|
| Market Structure | The market is moderately consolidated among large multinational biologics manufacturers, alongside specialized biosimilar, plasma-derived, cell-therapy and biotechnology companies . |
| Innovation Focus | GLP-1 franchise expansion, antibody-drug conjugates, and closed-system cell therapy manufacturing dominate current innovation pipelines across leading originators. |
| M&A Activity | Active, with large originators continuing to acquire clinical-stage cell, gene, and nucleic acid therapy developers to diversify pipelines beyond mature antibody and peptide franchises. |
Companies compete primarily on pipeline depth, regulatory approval velocity, and manufacturing scale across the Biologicals Market. Eli Lilly and Company and Novo Nordisk A/S compete directly within the GLP-1 metabolic disease category on recombinant insulin and peptide manufacturing capacity, while Sandoz Group AG and Amgen Inc. compete on biosimilar portfolio breadth and manufacturing cost efficiency.
Two archetypes dominate the market: diversified originator companies with broad small-molecule and biologics portfolios, and specialized biologics-focused manufacturers concentrated on antibody, peptide, or plasma-derived categories. Roche Holding AG and Johnson & Johnson exemplify the diversified archetype through combined oncology, immunology, and device portfolios, while CSL Limited and Grifols, S.A. exemplify the specialized archetype built around plasma-derived therapy manufacturing depth.
Innovation and differentiation strategy increasingly center on oral peptide delivery and next-generation antibody engineering. Eli Lilly's 2026 FDA approval of Foundayo , the first GLP-1 pill without food and water timing restrictions, illustrates how originators are extending metabolic disease franchises into oral formats to capture patients who decline injectable therapy. Companies unable to demonstrate differentiated delivery or efficacy profiles risk losing share to both biosimilars and next-generation competitors.
Portfolio diversification through acquisition continues to reshape competitive positioning within the market. Large originators facing biosimilar exposure on mature antibody franchises continue to acquire clinical-stage cell, gene, and nucleic acid therapy developers to rebuild long-term pipeline depth. This pattern illustrates how companies are using M&A to offset anticipated revenue erosion from patent expiry on their largest current biologic products.
The following 20 companies represent the validated competitive set actively shaping product innovation, regulatory strategy, and manufacturing investment within the global Biologicals Market.
Recent regulatory actions and corporate developments within the Biologicals Market are concentrated on GLP-1 franchise expansion and accelerating biosimilar approval activity.
| Date | Event |
|---|---|
| July 29, 2026 | Johnson & Johnson completed its $1 billion acquisition of Firefly Bio, adding the Firelink degrader-antibody conjugate platform and programs targeting pan-KRAS and other cancer drivers. The deal broadens J&J’s antibody-engineering capabilities and highlights strategic investment in emerging conjugate technologies that extend biologic targeting beyond conventional ADC designs. (JNJ.com) |
| July 6, 2026 | Novartis agreed to acquire Myricx Bio , gaining a novel N- myristoyltransferase inhibitor ( NMTi ) antibody-drug conjugate (ADC) payload platform and two lead ADC assets targeting B7-H3 and HER2. The transaction is intended to strengthen Novartis’ oncology pipeline with a differentiated payload mechanism designed to address limitations of established payload classes, including potential resistance to TOPO-1 inhibitor-based ADCs (Novartis) |
| June 29, 2026 | AstraZeneca and Daiichi Sankyo received European Union approval for Enhertu , a HER2-directed antibody-drug conjugate, as a tumor -agnostic therapy for previously treated HER2-positive metastatic solid tumors . The decision expands ADC use across multiple cancer types and reinforces the broader commercial and clinical role of targeted biologic medicines. (AstraZeneca) |
Capital inflows are increasingly directed toward GLP-1 manufacturing capacity and biosimilar-ready production infrastructure. Eli Lilly and Company continues to invest in incretin manufacturing capacity to meet rising demand, while Sandoz Group AG and other biosimilar-focused manufacturers are expanding production capacity ahead of anticipated patent expiries for several major monoclonal antibody franchises through 2030.
Infrastructure investment in cell therapy manufacturing and cold-chain distribution networks is expanding the operational foundation required for broader biologics access. Manufacturers continue to build automated, closed-system production facilities to reduce per-patient cell therapy manufacturing cost and shorten vein-to-vein turnaround time. This infrastructure investment is increasingly concentrated in regions with established regulatory qualification pathways, including the United States, the European Union, and South Korea.
Environmental and governance considerations specific to biologics manufacturing include single-use bioreactor plastic waste, the energy intensity of cold-chain distribution, and equitable pricing access for high-cost cell and gene therapies. Manufacturers face growing scrutiny over list pricing for single-administration therapies exceeding several hundred thousand dollars per patient. Investors increasingly evaluate manufacturing resilience, including geographic diversification of fill-finish capacity, as a governance factor following pandemic-era supply disruptions.
Enterprise and industry leaders gain validated segmentation, competitive benchmarking, and regional demand forecasts that support portfolio and manufacturing investment decisions across the Biologicals Market. Detailed product modality, therapeutic area, and distribution channel breakdowns help portfolio teams identify underserved categories and anticipate biosimilar competitive timing for their own franchises.
Investors and financial analysts gain consistent, single-point market size and CAGR estimates that support valuation and capital-allocation decisions across the Biologicals Market manufacturer landscape. The report's segment and regional growth differentials help identify which companies are positioned to capture above-market growth in metabolic disease and nucleic acid therapeutic categories through 2035.
Technology vendors and product teams gain insight into manufacturing and delivery requirements, including closed-system cell therapy production and oral peptide formulation, that are reshaping the Biologicals Market. This analysis helps R&D teams prioritize development roadmaps around regulatory approval pathways and manufacturing scalability increasingly required by originator and biosimilar sponsors alike.
The long-term outlook for the Biologicals Market remains strongly positive. Global revenue is projected to expand from USD 657.51 Billion in 2025 to USD 1,659.47 Billion by 2035 at a 9.7% CAGR. GLP-1 franchise expansion and accelerating biosimilar competition will jointly determine which categories capture the largest share of this growth through the forecast period.
Originator companies should prioritize lifecycle management strategies, including next-generation formulations and combination therapies, ahead of anticipated biosimilar entry on major franchises. Companies investing early in oral peptide delivery and closed-system cell therapy manufacturing will be best positioned to defend premium pricing within the Biologicals Market.
The market presents a highly attractive investment case, supported by a USD 938.18 Billion absolute dollar opportunity between 2026 and 2035 and above-average growth in Asia-Pacific and endocrine and metabolic disease categories. Manufacturers combining scaled manufacturing capacity with differentiated pipeline assets are best positioned to capture growth across both originator and biosimilar market segments.
Stakeholders should monitor accelerating biosimilar approval activity, high per-patient cell and gene therapy costs, and cold-chain infrastructure gaps in emerging markets as key risks to the Biologicals Market. Companies unable to demonstrate differentiated efficacy or delivery advantages over biosimilar competitors risk losing share on their largest current revenue-generating franchises.
Priority growth pathways include expanding oral peptide formulations, scaling nucleic acid therapeutic pipelines, and deepening biosimilar manufacturing investment across Asia-Pacific markets. Companies pursuing these pathways while maintaining regulatory compliance across major markets will be best positioned to capture the market's projected growth through 2035.
We have successfully delivered the following deep-dive customizations:
Liza Phukan is Research Associate at Next Move Strategy Consulting, where she has covered emerging industries and market research across sectors for 3.5 years. Her work includes analyzing industry developments, validating market data, and developing structured business content from research findings. She uses secondary research and data-validation practices to turn complex market information into clear decision-useful market analysis for business audiences and support report development and B2B.
Supradip Baul is an accomplished business consultant and strategist with over a decade of rich experience in market intelligence, strategy, technology, and business transformation. His work has included rigorous qualitative and quantitative analysis across multiple industries, helping clients shape investment decisions and long-term roadmaps. Earlier in his career, he was associated with Gartner, where he contributed to industry-leading reports and market share analyses. He has worked with leading global companies and holds an MBA with a dual specialization in Marketing and Finance.
Assistant Manager
We would like to express our appreciation for the data and insights provided by nextmsc. We are very pleased with the quality and depth of the information, which has proven to be highly valuable and beneficial for our business decision-making.
Director of Marketing
The information provided by NMSC is incredibly valuable, thank you so much for such a excellent work. I really appreciate it. I will make sure to reference all of it, in my summary document.
Business Insight Manager
“Next MSC have been incredibly helpful in providing detailed & robust information on our market, alongside quantifying growth by different segments. The process to procure was simple and easy, with sample reports and regular contact to ensure we had what we needed. Succinct detail on their sources & methodologies is also greatly received, allowing transparency in this respect helps build trust in the detail you pay for. Joseph in particular was fantastic, and helped ensure efficient provision of the insight pack – thank you NMSC!”.
Founder & CEO
The EV Charging market research report provided by the NextMSC was exceptionally detailed and insightful. It offered a comprehensive analysis that proved to be a game-changer for our strategic planning. Truly a testament to the NextMSC’s expertise and thoroughness in EV market landscape & analysis.
Co-Founder & Sales Manager
I work a lot in the marketing industry and I know that research is an essential part of any campaign. I have used Market research reports for my own products and I found them to be very informative and well-researched. The team here produces insightful reports for a good price
We will customize the research for you if the listed report does not fully match your requirements.
Get 30% Free Customization
U.S. Biologicals Market
Canada Biologicals Market
UK Biologicals Market
Germany Biologicals Market Outlook
France Biologicals Market
China Biologicals Market
India Biologicals Market
Japan Biologicals Market
South Korea Biologicals Market
Australia Biologicals Market
Saudi Arabia Biologicals Market
UAE Biologicals Market
South Africa Biologicals Market
Brazil Biologicals Market
Argentina Biologicals Market
